Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QN-019a in B-Cell Malignancies
NCT05379647Phase 1Unknown
- Sponsor
- Zhejiang University
- Start
- Nov 2021
- Primary completion
- Jun 2024
- Modality
- Allogeneic iPSCs, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of QN-019a in B cell lymphoma and B cell acute lymphoblastic leukemia (B-ALL) (2 arms), sponsored by Zhejiang University. Primary endpoints: Dose Limiting Toxicities at Day 28 and Treatment-Emergent Adverse Events at Day 28. Status: unknown.
02
Drugs
QN-019a
03
Conditions
B cell lymphomaB cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT05379647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05379647.